Background Women aged #35 years with breast cancer have a poor prognosis, but their prognostic factors have not been clearly defined. Aims To evaluate whether the molecular markers used in age-unspecified breast cancer could also be applied to women #35 years. Methods Archival tumours from patients aged #35 years with stage IeIII breast cancer were collected. Oestrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and P53 protein expression profiles in paraffin-embedded tissue sections were determined by immunohistochemistry. Tumours with an HER2 score of 2+ were further evaluated by fluorescence in situ hybridisation. Mutational analysis of exons 4e9 of the TP53 gene and exons 9 and 20 of the PIK3CA gene was carried out using direct sequencing analysis.
INTRODUCTION
Women under 35 years of age comprise a small proportion of patients with breast cancer 1 and have significantly worse survival than older patients. 2 3 Breast cancers in these young women are more frequently poorly differentiated, oestrogen receptor (ER) negative, and display a high proliferation index. However, these adverse pathological factors have been shown to only partially explain the survival difference between older and younger patients. Age younger than 35 years remained an independent predictor of poor outcome 4 5 and these cancers may be considered as a distinct disease entity.
Due to its relative rarity, the prognostic factors in women aged #35 years with breast cancer have yet to be firmly established. For example, the prognostic impact of ER and human epidermal growth factor receptor 2 (HER2) status, the two well established markers in age-unspecified breast cancer, remain controversial in this young population.
6e11
TP53 and PIK3CA mutations are two of the most common genetic alterations in human breast cancer. In age-unspecified patients, numerous studies have shown that TP53 mutations are predictive of poor prognosis. 12 13 Activating mutations in PIK3CA, the gene encoding the p110 catalytic subunit of PI3K, have been identified as novel mechanisms of inducing oncogenic PI3K signalling, 14 and therefore have become an attractive target for cancer treatment. 15 However, the prognostic role of these two common genetic alterations has also not been studied in women aged #35 years with breast cancer.
The present study aimed to comprehensively evaluate whether these common prognostic markers identified in age-unspecified breast cancer could be applied to women aged #35 years with breast cancer.
METHODS

Patients and sample collection
During the period January 1997 to December 2005, incident breast cancer stage IeIII was diagnosed in 181 consecutive female patients aged #35 at the National Taiwan University Hospital. Among them, archival breast tumour tissues from 116 patients were available for immunohistochemical and mutation analyses. Fifty-six patients had been included in our previous study describing association of age with molecular subtypes defined by immunohistochemistry. 16 The staging of breast cancer followed the American Joint Committee on Cancer (AJCC, 7th edition) criteria. Histological grade was categorised as grade I, II or III according to the Nottingham modification of the ScarffeBloomeRichardson criteria by a single pathologist. Patients' characteristics and clinical data were extracted from medical charts. In patients who were lost to follow-up, disease status and survival outcomes were obtained from medical charts, hospital cancer registry records and the National Death Certificate Registry system. The survival data used in this study were current as of 30 
Immunohistochemistry and fluorescence in situ hybridisation
The ER, progesterone receptor (PR) and HER2 status were evaluated as previously described. 16 For ER and PR, tumours with $10% positively stained nuclei were considered positive. 17 The HER2 status was considered positive if scored 3+ by immunohistochemical analysis or 2+ with gene amplification on fluorescence in situ hybridisation (FISH). 18 The immunohistochemical methods used for staining Ki67 and P53 protein expression have been previously reported 19 20 ; the primary antibodies were anti-Ki67 (1:200 dilution, clone (6) 24 (26) 5 (23) 1 24 (21) 21 (25) 3 (9) 18 (19) 6 (27) 2 34 (29) 23 (27) 11 (34) 31 (33) 3 (14) 3 29 (25) 13 (15) 16 (50) 21 (22) 8 (36) *Neoadjuvant and/or adjuvant therapy. AJCC, American Joint Committee on Cancer; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
MIB-1, DakoCytomation, Denmark) and anti-P53 (1:200 dilution, clone DO-7, DakoCytomation), respectively. The expression of Ki67 was regarded as positive if at least 20% of invasive cancer cells stained positive. 19 The intensity of P53 staining was rated semi-quantitatively on a four-point scale (0¼no staining, 1¼light staining, 2¼staining of moderate intensity and 3¼intense or maximum staining). The maximum intensity of staining in $10% positive staining tumour cells was scored for each tissue specimen; score 3 was considered positive. 20 PCR and direct sequencing of TP53 and PIK3CA H&E-stained slides of the tumours were reviewed and areas of tumour were marked for macrodissection to enrich tumour DNA. H&E-stained tissue sections (15 mm sections) were scraped off from glass slides. The genomic DNA of the macrodissected tumour specimens was isolated using the QIAamp DNA Mini Kit (Qiagen, Valencia, California, USA), amplified by PCR, and sequenced for the exons known to contain mutational hotspots. These exons included exons 4e9 of the TP53 gene and exons 9 and 20 of the PIK3CA gene. 21 22 The primers are listed in the supplementary table online. The amplified DNA was subjected to forward and reverse sequencing using an autosequencer (Applied Biosystems, CA, USA) with sequencing or corresponding PCR primers.
Statistical analysis
Disease-free survival was defined as the duration from diagnosis to either confirmation of disease recurrence, including local, regional and distant recurrences, or death due to breast cancer. Overall survival was defined as the duration from diagnosis to death due to any cause.
Survival curves were constructed using the KaplaneMeier method. The association between each of the categorical variables and survival was analysed by the log-rank test. Cox's proportional hazards analysis was used to determine the relative contribution of various factors to disease-free and overall survival. A p value #0.05 was used to indicate statistical significance; all tests were two-tailed. All statistical analyses were performed with the statistical package SPSS for Windows V.17.0. Table 1 summarises the demographic data of the 116 patients with and without TP53 and PIK3CA mutations. Eleven (11%) of 103 patients with available records had a family history of breast cancer; none had a family history of ovarian cancer. One of four patients who received BRCA1 and BRCA2 mutation analyses was identified to have BRCA1 mutation (T1691K). After surgery, the majority of patients (86 of 116, 75%) received adjuvant hormone treatment, including tamoxifen (n¼75), ovarian suppression plus tamoxifen (n¼6) and ovarian suppression plus aromatase inhibitors (n¼5). Eighty-six (74%) patients received neoadjuvant and/or adjuvant chemotherapy. The regimens included cyclophosphamide/methotrexate/5-fluorouracil in 4 patients, anthracycline-based regimens in 60 patients, anthracycline plus taxane-based regimens in 20 patients, and taxane plus cisplatin in 2 patients. Because the use of trastuzumab in the adjuvant setting had not been reimbursed by the national health insurance in Taiwan until 1 January 2010, only 2 patients with HER2-positive tumours received adjuvant trastuzumab in the present study. Table 2 presents details of mutations in the coding region of TP53. A total of 34 mutations, including 30 missense mutations and 2 nonsense mutations, were identified in 32 tumours. All of the TP53 mutations detected in this study had been previously reported in the IARC TP53 database (http://www-p53.iarc.fr/ MutationValidation Criteria.asp). As shown in table 1, TP53 mutations were negatively associated with ER expression (p¼0.004), marginally associated with HER2 overexpression (p¼0.055) and significantly associated with P53 expression (p<0.001). PIK3CA mutations found in this study included the H1047R missense mutation in exon 20 (n¼18), the E542K mutation in exon 9 (n¼2) and the E545K mutation in exon 9 (n¼2). As shown in table 1, tumours with PIK3CA mutations had a higher frequency of P53 protein expression (p¼0.027), but were not associated with the presence of TP53 mutations (data not shown, p¼0.622).
RESULTS
Clinical and pathological characteristics of patients
Univariate survival analyses of prognostic factors
The median follow-up duration was 62.7 months (95% CI 66.4 to 68.9). The 5-year disease-free survival rate was 89% for stage I disease, 71% for stage II disease and 48% for stage III disease.
The 5-year overall survival rate was 96% for stage I disease, 81% for stage II disease and 68% for stage III disease. Univariate analysis showed that larger tumour size, greater axillary lymph node involvement, high Ki67 proliferative index and TP53 mutations were significantly associated with poor disease-free and overall survival (table 3 and figure 1 ). HER2 overexpression and ER negativity were significantly associated with poor overall survival. PR and PIK3CA exon 20 and exon 9 mutations were not significantly associated with disease-free or overall survival.
Multivariate survival analyses of prognostic factors Table 4 presents results of logistic regression and Cox's proportional hazards analyses for disease-free and overall survival. In addition to axillary lymph node status and tumour size, TP53 mutation (HR¼3.76, p¼0.001) was an independent prognostic factor for poor disease-free survival, and high Ki67 expression (HR¼2.09, p¼0.052) was marginally associated with shorter disease-free survival. HER2 overexpression (HR¼3.21, p¼0.013), high Ki67 expression (HR¼3.93, p¼0.005) and TP53 mutations (HR¼4.44, p¼0.005) were independent predictors of poor overall survival.
DISCUSSION
This study showed that high Ki67 expression, HER2 overexpression and TP53 mutations were independent predictors of poor prognosis in women aged #35 years with breast cancer. Both Ki67 expression and TP53 mutation were better indicators of poor prognosis than histological grade and P53 expression. ER 23 In 2009, the St Gallen Consensus recommended using markers of proliferation, such as Ki67, to determine the optimum treatment for early breast cancer. 24 The present study shows that the prognostic value of Ki67 expression is superior to that of histological grade and supports the use of Ki67 assessment in women aged #35 years.
In this study, the rate of mutations in exons 4e9 of the TP53 gene was 28%, a mutation rate similar to that reported in ageunspecified populations, 12 and the prognostic impact is consistent with a meta-analysis of 3500 age-unspecified patients which showed that patients with TP53 mutations were more likely to develop disease recurrence (HR¼2.0, 95% CI 1.7 to 2.5).
12 Although P53 protein expression was significantly associated with the presence of TP53 mutation (p<0.001), P53 protein expression was only marginally associated with survival in our univariate analysis. A similar finding was reported in a meta-analysis involving more than 9800 patients, which showed that the prognostic value of P53 immunohistochemical expression in breast cancer was weak. 25 In this study, ER expression was associated with better overall survival in the univariate analysis but not in the multivariate analysis (p¼0.201, data not shown). When we controlled for TP53 mutations in the multivariate analysis, ER expression was still only marginally associated with longer overall survival (p¼0.065, data not shown). Our finding is consistent with results from the Danish Breast Cancer Cooperative Group who showed that very young patients with ER-positive tumours have significantly longer overall survival in the first 5 years but not 5e10 years after diagnosis. 8 The marginal prognostic value of ER and the lack of association between PR and survival in this study suggest that hormone receptor status is not a reliable predictor of prognosis in women #35 years of age.
The frequency of HER2 overexpression (25%) in this study is close to that in an age-unspecified breast cancer population. 26 The strong prognostic significance of HER2 shown in this study is consistent with the findings reported in two previous studies, 9 10 but differs from the frequency reported in a study conducted at the M.D. Anderson Cancer Center. 11 The PIK3CA mutation rate in this study was 19%, which is lower than the mutation rate in age-unspecified populations from previous reports (20e40%). 22 27 28 Therefore, we additionally examined the frequency of PIK3CA mutations in breast carcinoma specimens from 74 patients aged >35 years and found that the PIK3CA mutation frequency was 31% (data not shown). The association of PIK3CA mutations with older age is consistent with that reported by Kalinsky et al. 22 Although the presence of PIK3CA mutations has been linked to both favourable 22 29 30 and unfavourable 27 prognosis, the present study and two previous reports show no association between the presence of PIK3CA mutations and patients' prognosis. 28 31 In summary, we found a strong prognostic impact of TP53 mutations, and Ki67 and HER2 expression, and limited prognostic value of hormone receptor expressions in women #35 years. The limited prognostic value of hormone receptors suggests that the prognostic molecular markers used in ageunspecified breast cancer may not be completely suitable for this young population.
Take-home messages < High Ki67 expression, human epidermal growth factor receptor 2 (HER2) overexpression and TP53 mutations are strong predictors of poor prognosis in women #35 years with breast cancer. < The prognostic value of oestrogen receptors is only marginal, and progesterone receptor expression and PIK3CA mutations are not associated with survival in the young population. < The common prognostic molecular markers used in ageunspecified breast cancer may not be completely suitable for women #35 years.
